v3.26.1
Condensed Consolidated Statements Of Changes In Stockholders’ (Deficit) Equity (Unaudited) - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Stock Subscription Receivable
Total
Balance at Dec. 31, 2024 $ 13,169 $ 101,998,956 $ (122,368,539) $ (2,545,586) $ (22,902,000)
Balance (in Shares) at Dec. 31, 2024 2,633,956        
Shares issued from exercise of Series A Warrants $ 74 241,472 241,546
Shares issued from exercise of Series A Warrants (in Shares) 14,755        
Conversion of convertible notes into common stock $ 339 527,161 527,500
Conversion of convertible notes into common stock (in Shares) 67,895        
Shares issued to consultants $ 1 670 671
Shares issued to consultants (in Shares) 100        
Reverse stock split $ (13,311) 13,311
Stock-based compensation 754,361 754,361
Net loss (income) 9,194,630 9,194,630
Balance at Mar. 31, 2025 $ 272 103,535,931 (113,173,909) (2,545,586) (12,183,292)
Balance (in Shares) at Mar. 31, 2025 2,716,706        
Balance at Dec. 31, 2024 $ 13,169 101,998,956 (122,368,539) (2,545,586) (22,902,000)
Balance (in Shares) at Dec. 31, 2024 2,633,956        
Balance at Dec. 31, 2025 $ 746 159,027,646 (163,372,539) (2,841,427) (7,185,574)
Balance (in Shares) at Dec. 31, 2025 7,465,283        
Shares issued upon settlement of warrants $ 24 (24)
Shares issued upon settlement of warrants (in Shares) 240,400        
Forward Purchase Agreement – subscription receivable discount 78,247 (78,247)
Discount on short term notes payable 70,000 70,000
Stock-based compensation to consultants $ 4 (4)
Stock-based compensation to consultants (in Shares) 40,000        
Stock-based compensation 277,654 277,654
Net loss (income) (1,430,668) (1,430,668)
Balance at Mar. 31, 2026 $ 774 $ 159,453,519 $ (164,803,207) $ (2,919,674) $ (8,268,588)
Balance (in Shares) at Mar. 31, 2026 7,745,683